Skip to content

Elise Rundén-Pran

Senior Scientist / Head of Section for the Health Effects Laboratory

+47 970 15 315

+47 63 89 82 37

Environmental Chemistry and Health Effects

Kjeller

erp@nilu.no

Elise Rundén Pran

About

Dr. Elise Rundén-Pran is a senior scientist at NILU in the department of Environmental Chemistry and Health Effects. She is section leader for the Health Effects Laboratory and an ERT registered toxicologist.

She has extensive experience in toxicology, nanotoxicology, nanosafety, cell cultures, 3D-cellular models, nanogenotoxicology, DNA damage, intracellular cell death signaling, microscopy (confocal, TEM), immunohistochemistry, tissue slice cultures and neurodegeneration.

She was part of the Centre for Excellence in Molecular Neurobiology and DNA repair (UiO) for several years (PhD and Postdoc). She is experienced with human risk assessment and regulatory toxicology, partner leader in EURONANOMED II projects GEMNS and INNOCENT, and NILU project leader for several projects funded by EU and NFR. She has extensive experience in GLP, and is appointed member of the national committee for approval of European registered toxicologists (ERT), The Norwegian Scientific Committee for Food and Environment, and member of the national expert group for toxicology.

The Health Effects Laboratory is certified for Good Laboratory Practice (GLP) for in vitro human toxicity studies. The laboratory is among the leading laboratories in Europe in nanotoxicology and nanosafety, and main areas of interest are genotoxicity, carcinogenicity in vitro, epigenetics, advanced in vitro models, regulatory aspects of nanosafety,  high-throughput approach to toxicity testing, intelligent testing strategy and adverse outcome pathways.

Publications at NILU

Partnership for the Assessment of Risks from Chemicals (PARC)

PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies with new data, knowledge, methods, networks and skills to […]

Project period: 2022 – 2029

Ongoing

PARC - Partnership for the Assessment of Risks from Chemicals

PARC is a very large EU-funded project with almost 200 partners in 28 countries running in the period 2021 – 2027. The project is coordinated by ANSES, the French Agency […]

Project period: 2022 – 2029

Ongoing

Strengthening the integrated approach of holistic impact assessments for Safe and Sustainable by Design plastic value chain (ANALYST)

ANALYST aims to accelerate the transition towards a safer and more sustainable industrial value chain while encouraging and expanding the existing knowledge on the safe and sustainable by design (SSbD) […]

Project period: 2024 – 2027

Ongoing

PEST-TOX, Eksponering for plantevernmidler og mulig betydning for human helse

Pesticides are used to prevent crop damage in agriculture and forestry caused by fungi, pests, and weeds. Since the 1960s, there has been concern about the harmful effects pesticides can […]

Project period: 2025 – 2027

Ongoing

Enhanced Safe and Sustainable coatings for supporting the Planet (PROPLANET)

PROPLANET addresses novel coating materials solutions, tackling the problem from a sustainable-business perspective, enabling overcoming the barrier for environmental protection, safety, chemical improvements, and circular value chains. The main goal […]

Project period: 2023 – 2026

Concluded

CeO2 Nanoparticles-assisted stem-based cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases (CELLUX)

The main aim of the CELLUX project was to develop a novel pharmaceutical based on CeO2 nanoparticles (NPs) in the form of eye drops to treat Age-Related Macular Degeneration (AMD). […]

Project period: 2020 – 2025

Concluded

The establishment of advanced cell therapy for the treatment of limbal stem cell deficiency in the Czech Republic. KAPPA

This project aims at the development of a new type of LSCD treatment using advanced therapy medicinalproducts (ATMP). It is a direct continuation of a previous research project of the […]

Project period: 2021 – 2024

Concluded

Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers (VISION)

Slovakia belongs to countries with the highest incidence of colorectal and pancreatic cancer in Europe. Therefore, the main goal of the VISION proposal is to strengthen the scientific excellence and […]

Project period: 2019 – 2022

Concluded

Behandling av hjerneslag med glutamat oksaloacetate transaminase nanopartikler (GOTTARG)

The project will develop and test the first targeted and long-acting nanomedicine with neuroprotective properties for ischemic stroke, with potential application in other neurological diseases. The Team will demonstrate that […]

Project period: 2020 – 2022

Concluded

Towards a reliable assessment of nanomaterial health effects using advanced biological models and assays (NanoBioReal)

A sound scientific basis is needed to assess the risks to workers and consumers, to inform regulatory bodies and to ensure a responsible development of nanotechnology. Most of the existing […]

Project period: 2019 – 2022

Concluded

Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy (INNOCENT)

A challenge in the treatment of breast cancer patients is frequent relapses. This project focuses at circulating cancer stem cells, which are a main cause of relapses in the patients. […]

Project period: 2017 – 2020

Concluded

Partnership for the Assessment of Risks from Chemicals (PARC)

PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies with new data, knowledge, methods, networks and skills to […]

Project period: 2022 – 2029

Ongoing

PARC - Partnership for the Assessment of Risks from Chemicals

PARC is a very large EU-funded project with almost 200 partners in 28 countries running in the period 2021 – 2027. The project is coordinated by ANSES, the French Agency […]

Project period: 2022 – 2029

Ongoing

Strengthening the integrated approach of holistic impact assessments for Safe and Sustainable by Design plastic value chain (ANALYST)

ANALYST aims to accelerate the transition towards a safer and more sustainable industrial value chain while encouraging and expanding the existing knowledge on the safe and sustainable by design (SSbD) […]

Project period: 2024 – 2027

Ongoing

PEST-TOX, Eksponering for plantevernmidler og mulig betydning for human helse

Pesticides are used to prevent crop damage in agriculture and forestry caused by fungi, pests, and weeds. Since the 1960s, there has been concern about the harmful effects pesticides can […]

Project period: 2025 – 2027

Ongoing

Enhanced Safe and Sustainable coatings for supporting the Planet (PROPLANET)

PROPLANET addresses novel coating materials solutions, tackling the problem from a sustainable-business perspective, enabling overcoming the barrier for environmental protection, safety, chemical improvements, and circular value chains. The main goal […]

Project period: 2023 – 2026

Concluded

CeO2 Nanoparticles-assisted stem-based cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases (CELLUX)

The main aim of the CELLUX project was to develop a novel pharmaceutical based on CeO2 nanoparticles (NPs) in the form of eye drops to treat Age-Related Macular Degeneration (AMD). […]

Project period: 2020 – 2025

Concluded

The establishment of advanced cell therapy for the treatment of limbal stem cell deficiency in the Czech Republic. KAPPA

This project aims at the development of a new type of LSCD treatment using advanced therapy medicinalproducts (ATMP). It is a direct continuation of a previous research project of the […]

Project period: 2021 – 2024

Concluded

Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers (VISION)

Slovakia belongs to countries with the highest incidence of colorectal and pancreatic cancer in Europe. Therefore, the main goal of the VISION proposal is to strengthen the scientific excellence and […]

Project period: 2019 – 2022

Concluded

Behandling av hjerneslag med glutamat oksaloacetate transaminase nanopartikler (GOTTARG)

The project will develop and test the first targeted and long-acting nanomedicine with neuroprotective properties for ischemic stroke, with potential application in other neurological diseases. The Team will demonstrate that […]

Project period: 2020 – 2022

Concluded

Towards a reliable assessment of nanomaterial health effects using advanced biological models and assays (NanoBioReal)

A sound scientific basis is needed to assess the risks to workers and consumers, to inform regulatory bodies and to ensure a responsible development of nanotechnology. Most of the existing […]

Project period: 2019 – 2022

Concluded

Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy (INNOCENT)

A challenge in the treatment of breast cancer patients is frequent relapses. This project focuses at circulating cancer stem cells, which are a main cause of relapses in the patients. […]

Project period: 2017 – 2020

Concluded